CTOs on the Move

Allied Research International

www.allied-research.com

 
Allied Research International is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Dent Neurologic Institute

The DENT Neurologic Institute is among the largest, most comprehensive neurology practices in the United States. We are focused on providing superior clinical care, advanced diagnostic services, clinical research, and education.

Net-Rx

Net-Rx is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Genius Therapy

Genius Therapy LLC is an early intervention agency that was founded to promote and enhance the development of infants and young children with special needs between the ages of birth to three. Our mission is for all children with special needs to achieve their maximum personal development both as individuals and as learners. At Genius Therapy, we develop programs designed specifically for each child, utilizing the principles of special instruction, applied behavioral analysis, occupational therapy and speech and language therapy.

Mccrone Group Inc

Mccrone Group Inc is a Westmont, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.